Sort
10,766 grants matching “checkpoint inhibitor”
Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma
$638,550Veronika Fedirko · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Nano immunoconjugates to treat primary and metastatic HER2 positive breast cancer
$638,279Julia Y Ljubimova · Cedars-Sinai Medical Center · R01 · FY2019 · CA
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$638,124Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Project 3: Tools for Capturing Immune Cell/Cancer Cell Interactions in Cancer Immunotherapies and Combination Immunotherapies
$637,991James R. Heath · California Institute Of Technology · U54 · FY2015 · CA
Nano immunoconjugates to treat primary and metastatic HER2 positive breast cancer
$637,908Julia Y Ljubimova · Cedars-Sinai Medical Center · R01 · FY2020 · CA
Drug eluting injectable biomaterials for next generation chemoembolization
$637,881Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2023 · CA
Preclinical and Clinical Models of Drug Induced Kidney Injury
$637,693Melanie S Joy · University Of Colorado Denver · R01 · FY2023 · CA
Role of AMPK in melanoma brain metastasis
$637,432Bin Zheng · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Lynch Vaccine
$637,348Julie Magarian Blander · Weill Medical Coll Of Cornell Univ · U54 · FY2025 · CA
Adaptive Symptom Self-Management to Reduce Psychological Distress and Improve Symptom Management for Survivors on Immune Checkpoint Inhibitors
$637,302Terry A Badger · University Of Arizona · R01 · FY2023 · CA
Mechanisms of Immune Dysfunction and Morbid Outcome in Response to Shock/Sepsis
$637,098Alfred Ayala · Rhode Island Hospital · R35 · FY2018 · GM
Mechanisms of Immune Dysfunction and Morbid Outcome in Response to Shock/Sepsis
$637,098Alfred Ayala · Rhode Island Hospital · R35 · FY2017 · GM
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer
$637,054Michelle S Bradbury · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Enhancing cell therapy for brain tumors
$636,818Catherine Mary Bollard · Children'S Research Institute · U01 · FY2022 · CA
Enhancing cell therapy for brain tumors
$636,807Catherine Mary Bollard · Children'S Research Institute · U01 · FY2020 · CA
Enhancing cell therapy for brain tumors
$636,799Catherine Mary Bollard · Children'S Research Institute · U01 · FY2019 · CA
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
$636,708Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2018 · CA
Image-guided cancer therapy using heat activatable CAR T cells
$636,703Stanislav Y Emelianov · Georgia Institute Of Technology · R01 · FY2024 · EB
Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
$636,627Darell D Bigner · Duke University · R35 · FY2017 · CA
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
$636,517Paul E Kinahan · University Of Washington · U24 · FY2025 · CA
Image-guided ultrasound therapy and drug delivery in pancreatic cancer
$636,467Katherine W Ferrara · University Of California At Davis · R01 · FY2016 · CA
Image-guided ultrasound therapy and drug delivery in pancreatic cancer
$636,467Katherine W Ferrara · University Of California At Davis · R01 · FY2017 · CA
Enhancing cell therapy for brain tumors
$636,455Catherine Mary Bollard · Children'S Research Institute · U01 · FY2021 · CA
Targeting STAT3 to enhance anti-tumor immunity
$636,402Daniel E Johnson · University Of California, San Francisco · R01 · FY2020 · DE
Targeting STAT3 to enhance anti-tumor immunity
$636,402Daniel E Johnson · University Of California, San Francisco · R01 · FY2021 · DE